Literature DB >> 11089838

Pharmacogenetics and adverse drug reactions.

U A Meyer1.   

Abstract

Polymorphisms in the genes that code for drug-metabolising enzymes, drug transporters, drug receptors, and ion channels can affect an individual's risk of having an adverse drug reaction, or can alter the efficacy of drug treatment in that individual. Mutant alleles at a single gene locus are the best studied individual risk factors for adverse drug reactions, and include many genes coding for drug-metabolising enzymes. These genetic polymorphisms of drug metabolism produce the phenotypes of "poor metabolisers" or "ultrarapid metabolisers" of numerous drugs. Together, such phenotypes make up a substantial proportion of the population. Pharmacogenomic techniques allow efficient analysis of these risk factors, and genotyping tests have the potential to optimise drug therapy in the future.

Mesh:

Substances:

Year:  2000        PMID: 11089838     DOI: 10.1016/S0140-6736(00)03167-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  107 in total

1.  Pharmacogenetics and pharmacogenomics.

Authors:  M Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 2.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

Review 3.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

4.  Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine.

Authors:  B A Kaskas; E Louis; U Hindorf; E Schaeffeler; J Deflandre; F Graepler; K Schmiegelow; M Gregor; U M Zanger; M Eichelbaum; M Schwab
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

5.  SNP genotyping on a genome-wide amplified DOP-PCR template.

Authors:  Struan F A Grant; Simone Steinlicht; Ulrike Nentwich; Rainer Kern; Barbara Burwinkel; Ralf Tolle
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

Review 6.  Drug-induced myelosuppression : diagnosis and management.

Authors:  Peter J Carey
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  The role of cost-effectiveness analysis in the era of pharmacogenomics.

Authors:  Christopher R Flowers; David Veenstra
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

8.  Large-scale single-nucleotide polymorphism (SNP) and haplotype analyses, using dense SNP Maps, of 199 drug-related genes in 752 subjects: the analysis of the association between uncommon SNPs within haplotype blocks and the haplotypes constructed with haplotype-tagging SNPs.

Authors:  Naoyuki Kamatani; Akihiro Sekine; Takuya Kitamoto; Aritoshi Iida; Susumu Saito; Akifumi Kogame; Eisuke Inoue; Manabu Kawamoto; Masayoshi Harigai; Yusuke Nakamura
Journal:  Am J Hum Genet       Date:  2004-06-16       Impact factor: 11.025

9.  Inference from the relationships between linkage disequilibrium and allele frequency distributions of 240 candidate SNPs in 109 drug-related genes in four Asian populations.

Authors:  Pei-Chieng Cha; Ryo Yamada; Akihiro Sekine; Yusuke Nakamura; Chong-Lek Koh
Journal:  J Hum Genet       Date:  2004-09-11       Impact factor: 3.172

Review 10.  Data-driven methods to discover molecular determinants of serious adverse drug events.

Authors:  A P Chiang; A J Butte
Journal:  Clin Pharmacol Ther       Date:  2009-01-28       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.